Terms: = Skin cancer AND ZNF198, Q9UBW7, SCLL, RAMP, MYM, FIM, 7750
8 results:
1. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
2. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract] [Full Text] [Related]
3. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.
Shain AH; Joseph NM; Yu R; Benhamida J; Liu S; Prow T; Ruben B; North J; Pincus L; Yeh I; Judson R; Bastian BC
Cancer Cell; 2018 Jul; 34(1):45-55.e4. PubMed ID: 29990500
[TBL] [Abstract] [Full Text] [Related]
4. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract] [Full Text] [Related]
5. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract] [Full Text] [Related]
6. Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors.
Witze ES; Litman ES; Argast GM; Moon RT; Ahn NG
Science; 2008 Apr; 320(5874):365-9. PubMed ID: 18420933
[TBL] [Abstract] [Full Text] [Related]
7. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers.
Chatterjee N; Hartge P; Cerhan JR; Cozen W; Davis S; Ishibe N; Colt J; Goldin L; Severson RK
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1415-21. PubMed ID: 15342441
[TBL] [Abstract] [Full Text] [Related]
8. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia.
Baer SC; Casaubon L; Younes M
J Am Acad Dermatol; 1997 Oct; 37(4):575-7. PubMed ID: 9344196
[TBL] [Abstract] [Full Text] [Related]
